Refractory Diffuse Large B-cell Lymphoma: Clinical Trials

13 trials for Refractory Diffuse Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Completed 13
Phase 16Completed 6

Follow Refractory Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-cell Lymphoma trials Research Report on Refractory Diffuse Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2CompletedBeiGene532022-04-252025-09-15
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Phase 2CompletedBeiGene652021-08-112026-03-25
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2CompletedM.D. Anderson Cancer Center222020-07-272025-01-28
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2CompletedUniversity of Washington202020-06-052026-06-26
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Copanlisib Hydrochloride, Nivolumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)122019-12-132025-03-03
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)82018-10-242023-09-21
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedOhio State University Comprehensive Cancer Center192018-09-102025-05-14
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells - Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2CompletedM.D. Anderson Cancer Center222017-10-102023-02-16
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Phase 1 / Phase 2CompletedDavid Bond, MD362017-02-142026-09-23
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202 - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 2CompletedUniversity of Nebraska132016-10-072023-10-05
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedPharmacyclics LLC.1382014-03-132022-02-04
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center2042013-05-222022-05-25
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
Laboratory Biomarker Analysis, Ruxolitinib Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Phase 2CompletedUniversity of Nebraska712011-08-122023-10-05

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (13)  ·  Lymphoma, Follicular (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Burkitt Lymphoma (1)  ·  Hematologic Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, T-Cell (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Waldenstrom Macroglobulinemia (1)

Broader conditions

Hemic and Lymphatic Diseases (13)  ·  Immune System Diseases (13)  ·  Immunoproliferative Disorders (13)  ·  Lymphatic Diseases (13)  ·  Lymphoma, B-Cell (13)  ·  Lymphoproliferative Disorders (13)  ·  Neoplasms by Histologic Type (13)  ·  Lymphoma (12)  ·  Neoplasms (12)  ·  Lymphoma, Non-Hodgkin (10)  ·  Hematologic Diseases (4)  ·  Blood Protein Disorders (2)  ·  Cardiovascular Diseases (2)  ·  Chronic Disease (2)  ·  Disease Attributes (2)

Interventions

Lenalidomide (3)  ·  Nivolumab (3)  ·  Rituximab (3)  ·  Carmustine (2)  ·  Cytarabine (2)  ·  Etoposide (2)  ·  Melphalan (2)  ·  ibrutinib (2)  ·  CT-P10 (1)  ·  Cyclophosphamide (1)  ·  Disulfides (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Hematopoietic Stem Cell Transplantation (1)  ·  Immunoglobulin G (1)

Sponsors

BeiGene (2)  ·  M.D. Anderson Cancer Center (2)  ·  National Cancer Institute (NCI) (2)  ·  University of Nebraska (2)  ·  David Bond, MD (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Pharmacyclics LLC. (1)  ·  University of Washington (1)

Countries

United States (11)  ·  China (2)  ·  Belgium (1)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

David Bond, MD (1)  ·  Erel Joffe (1)  ·  Jordan Gauthier (1)  ·  Julie M Vose, MD, MBA (1)  ·  Jutta K. Neuenburg, MD, PhD (1)  ·  Kami Maddocks, MD (1)  ·  Matthew A Lunning, DO (1)  ·  Nabila N Bennani (1)  ·  Paolo Strati (1)  ·  Rahul Banerjee, MD (1)  ·  Yago L Nieto (1)

Results publications

PMID 27111235, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31331917, PMID 31648294, PMID 32967009, PMID 33942298, PMID 34515338, PMID 34666344, PMID 36618900, PMID 37774014, PMID 39333103, PMID 41595202, PMID 42389828

NIH funding

P30CA036727 (2), P50CA107399 (1), R01CA136551 (1), UM1CA186686 (1), UM1CA186691 (1), UM1CA186709 (1)